{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:26:47Z","timestamp":1788258407159,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>\u03b2-lapachone (\u03b2-lap), the NQO1 bioactivatable drug, is thought to be a promising anticancer agent. However, the toxic side effects of \u03b2-lap limit the drug use, highlighting the need for a thorough understanding of \u03b2-lap\u2019s mechanism of action. \u03b2-lap undergoes NQO1-dependent futile redox cycling, generating massive ROS and oxidative DNA lesions, leading to cell death. Thus, base excision repair (BER) pathway is an important resistance factor. XRCC1, a scaffolding component, plays a critical role in BER.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We knocked down XRCC1 expression by using pLVX-shXRCC1 in the MiaPaCa2 cells and BxPC3 cells and evaluated \u03b2-lap-induced DNA lesions by \u03b3H2AX foci formation and alkaline comet assay. The cell death induced by <jats:italic>XRCC1<\/jats:italic> knockdown + \u03b2-lap treatment was analysed by relative survival, flow cytometry and Western blotting analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that knockdown of <jats:italic>XRCC1<\/jats:italic> significantly increased \u03b2-lap-induced DNA double-strand breaks, comet tail lengths and cell death in PDA cells. Furthermore, we observed combining <jats:italic>XRCC1<\/jats:italic> knockdown with \u03b2-lap treatment switched programmed necrosis with \u03b2-lap monotherapy to caspase-dependent apoptosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results indicate that XRCC1 is involved in the repair of \u03b2-lap-induced DNA damage, and XRCC1 loss amplifies sensitivity to \u03b2-lap, suggesting targeting key components in BER pathways may have the potential to expand use and efficacy of \u03b2-lap for gene-based therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08979-y","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T15:02:48Z","timestamp":1637161368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["X-ray repair cross-complementing protein 1 (XRCC1) loss promotes \u03b2-lapachone \u2013induced apoptosis in pancreatic cancer cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Yansong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengce","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"1","key":"8979_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbcan.2015.04.003","volume":"2015","author":"D Singh","year":"1856","unstructured":"Singh D, Upadhyay G, Srivastava RK, Shankar S. Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochim Biophys Acta. 1856;2015(1):13\u201327. https:\/\/doi.org\/10.1016\/j.bbcan.2015.04.003.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"8979_CR2","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/cncr.32802","volume":"126","author":"SJ Henley","year":"2020","unstructured":"Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126(10):2225\u201349. https:\/\/doi.org\/10.1002\/cncr.32802.","journal-title":"Cancer."},{"issue":"2","key":"8979_CR3","doi-asserted-by":"publisher","first-page":"112182","DOI":"10.1016\/j.yexcr.2020.112182","volume":"395","author":"YS Zheng","year":"2020","unstructured":"Zheng YS, Chen ML, Lei WD, Zhu SL, You XQ, Liu YC. NUDT21 knockdown inhibits proliferation and promotes apoptosis of pancreatic ductal adenocarcinoma through EIF2 signaling. Exp Cell Res. 2020;395(2):112182. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112182.","journal-title":"Exp Cell Res"},{"key":"8979_CR4","doi-asserted-by":"publisher","unstructured":"Cutsem EV, Haustermans K, Steenbergen WV. New treatment possibilities for pancreatic and biliary tumors, Annals of Oncology Official Journal of the European Society for Medical Oncology. 2000;11(Suppl 3):165. https:\/\/doi.org\/10.1093\/annonc\/11.suppl_3.165.","DOI":"10.1093\/annonc\/11.suppl_3.165"},{"issue":"1","key":"8979_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/PAI.0b013e31802e91d0","volume":"16","author":"NS Awadallah","year":"2008","unstructured":"Awadallah NS, Dehn D, Shah RJ, Nash SR, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 2008;16(1):24\u201331. https:\/\/doi.org\/10.1097\/PAI.0b013e31802e91d0.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"20","key":"8979_CR6","doi-asserted-by":"publisher","first-page":"8088","DOI":"10.1158\/0008-5472.CAN-10-1418","volume":"70","author":"Y Dong","year":"2010","unstructured":"Dong Y, Bey EA, Li LS, Kabbani W, Yan JS, Xie XJ, et al. Prostate cancer radiosensitization through poly (ADP-ribose) polymerase-1 hyperactivation. Cancer Res. 2010;70(20):8088\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1418.","journal-title":"Cancer Res"},{"issue":"6","key":"8979_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ccell.2016.11.006","volume":"30","author":"XM Huang","year":"2016","unstructured":"Huang XM, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, et al. Leveraging an NQO1 Bioactivatable drug for tumor-selective use of poly (ADP-ribose) polymerase inhibitors. Cancer Cell. 2016;30(6):940\u201352. https:\/\/doi.org\/10.1016\/j.ccell.2016.11.006.","journal-title":"Cancer Cell"},{"issue":"5","key":"8979_CR8","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1038\/cddis.2014.202","volume":"5","author":"EJ Park","year":"2014","unstructured":"Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK. \u03b2-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014;5(5):e1230. https:\/\/doi.org\/10.1038\/cddis.2014.202.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8979_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/cr.2008.7","volume":"18","author":"JK Horton","year":"2008","unstructured":"Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase \u03b2 in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18(1):48\u201363. https:\/\/doi.org\/10.1038\/cr.2008.7.","journal-title":"Cell Res"},{"issue":"5","key":"8979_CR10","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/nar\/gkt025","volume":"41","author":"C Anna","year":"2013","unstructured":"Anna C, Thierry K, Rachel A, Herv\u00e9 M, Wim V. J Pablo R. distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic Acids Res. 2013;41(5):3115\u201329. https:\/\/doi.org\/10.1093\/nar\/gkt025.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"8979_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s10571-016-0425-5","volume":"37","author":"YC Liu","year":"2017","unstructured":"Liu YC, Gao XX, Zhang ZG, Lin ZH, Zou QL. PPAR gamma coactivator 1 beta (PGC-1\u03b2) reduces mammalian target of rapamycin (mTOR) expression via a SIRT1-dependent mechanism in neurons. Cell Mol Neurobiol. 2017;37(5):879\u201387. https:\/\/doi.org\/10.1007\/s10571-016-0425-5.","journal-title":"Cell Mol Neurobiol"},{"issue":"9","key":"8979_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.dnarep.2013.06.004","volume":"12","author":"JK Horton","year":"2013","unstructured":"Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, et al. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. Dna Repair. 2013;12(9):774\u201385. https:\/\/doi.org\/10.1016\/j.dnarep.2013.06.004.","journal-title":"Dna Repair"},{"issue":"3","key":"8979_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1097-2765(02)00482-3","volume":"9","author":"Y Shi","year":"2002","unstructured":"Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002 Mar;9(3):459\u201370. https:\/\/doi.org\/10.1016\/s1097-2765(02)00482-3.","journal-title":"Mol Cell"},{"issue":"5","key":"8979_CR14","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/srep17066","volume":"25","author":"G Chakrabarti","year":"2015","unstructured":"Chakrabarti G, Silvers MA, Ilcheva M, Liu YL, Moore ZR, Luo XQ, et al. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, \u03b2-lapachone. Sci Rep. 2015;25(5):17066. https:\/\/doi.org\/10.1038\/srep17066.","journal-title":"Sci Rep"},{"issue":"28","key":"8979_CR15","doi-asserted-by":"publisher","first-page":"11832","DOI":"10.1073\/pnas.0702176104","volume":"104","author":"EA Bey","year":"2007","unstructured":"Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1- and PARP1- mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A. 2007;104(28):11832\u20137. https:\/\/doi.org\/10.1073\/pnas.0702176104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"8979_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41416-018-0278-4","volume":"119","author":"DE Gerber","year":"2018","unstructured":"Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, et al. Phase 1 study of ARQ 761, a \u03b2-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer. 2018;119(8):928\u201336. https:\/\/doi.org\/10.1038\/s41416-018-0278-4.","journal-title":"Br J Cancer"},{"issue":"51","key":"8979_CR17","doi-asserted-by":"publisher","first-page":"16505","DOI":"10.1021\/bi048615m","volume":"43","author":"RS Mani","year":"2004","unstructured":"Mani RS, Karimi-Busheri F, Fanta M, Caldecott KW, Cass CE, Weinfeld M. Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry. 2004;43(51):16505\u201314. https:\/\/doi.org\/10.1021\/bi048615m.","journal-title":"Biochemistry"},{"issue":"1","key":"8979_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2199-8-81","volume":"8","author":"O Mortusewicz","year":"2007","unstructured":"Mortusewicz O, Leonhardt H. XRCC1 and PCNA are loading platforms with distinct kinetic properties and different capacities to respond to multiple DNA lesions. BMC Mol Biol. 2007;8(1):81. https:\/\/doi.org\/10.1186\/1471-2199-8-81.","journal-title":"BMC Mol Biol"},{"issue":"2","key":"8979_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1006\/dbio.1999.9232","volume":"208","author":"RS Tebbs","year":"1999","unstructured":"Tebbs RS, Flannery ML, Meneses JJ, Hartmann A, Tucker JD, Thompson LH, et al. Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. Dev Biol. 1999;208(2):513\u201329. https:\/\/doi.org\/10.1006\/dbio.1999.9232.","journal-title":"Dev Biol"},{"issue":"11","key":"8979_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/BF03402095","volume":"5","author":"L Huang","year":"1999","unstructured":"Huang L, Pardee AB. beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells. Mol Med. 1999;5(11):711\u201320. https:\/\/doi.org\/10.1007\/BF03402095.","journal-title":"Mol Med"},{"issue":"1","key":"8979_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0248-4900(01)01175-3","volume":"94","author":"J Kumi-Diaka","year":"2002","unstructured":"Kumi-Diaka J. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone. Biol Cell. 2002;94(1):37\u201344. https:\/\/doi.org\/10.1016\/s0248-4900(01)01175-3.","journal-title":"Biol Cell"},{"issue":"21","key":"8979_CR22","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.4161\/cc.5.21.3394","volume":"5","author":"M Menacho-M\u00e1rquez","year":"2006","unstructured":"Menacho-M\u00e1rquez M, Murgu\u00eda JR. Beta-lapachone activates a Mre11p-Tel1p G1\/S checkpoint in budding yeast. Cell Cycle. 2006;5(21):2509\u201316. https:\/\/doi.org\/10.4161\/cc.5.21.3394.","journal-title":"Cell Cycle"},{"issue":"3","key":"8979_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4062\/biomolther.2014.026","volume":"22","author":"HY Yu","year":"2014","unstructured":"Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH, et al. \u03b2-Lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K\/Akt pathway. Biomolecules and Therapeutics. 2014;22(3):184\u201392. https:\/\/doi.org\/10.4062\/biomolther.2014.026.","journal-title":"Biomolecules and Therapeutics"},{"issue":"4","key":"8979_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/1534735416681638","volume":"16","author":"JY Kee","year":"2017","unstructured":"Kee JY, Han YH, Park J, Kim DS, Mun JG, Ahn KS, et al. \u03b2-Lapachone inhibits lung metastasis of colorectal Cancer by inducing apoptosis of CT26 cells. Integr Cancer Ther. 2017;16(4):585\u201396. https:\/\/doi.org\/10.1177\/1534735416681638.","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"8979_CR25","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1038\/cddis.2014.202","volume":"5","author":"EJ Park","year":"2014","unstructured":"Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK. \u03b2-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014;5(5):e1230. https:\/\/doi.org\/10.1038\/cddis.2014.202.","journal-title":"Cell Death Dis"},{"key":"8979_CR26","doi-asserted-by":"publisher","first-page":"8995","DOI":"10.12659\/MSM.915463","volume":"25","author":"Y Han","year":"2019","unstructured":"Han Y, Shi D, Li J. Inhibition of nasopharyngeal carcinoma by Beta-Lapachone occurs by targeting the mammalian target of rapamycin (mTOR)\/PI3K\/AKT pathway, reactive oxygen species (ROS) production, and autophagy induction. Med Sci Monit. 2019;25:8995\u20139002. https:\/\/doi.org\/10.12659\/MSM.915463.","journal-title":"Med Sci Monit"},{"issue":"14","key":"8979_CR27","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1093\/nar\/gkv623","volume":"43","author":"B Claire","year":"2015","unstructured":"Claire B, Peter H, Andrew R, Stuart LR, Hana H, Antony WO, et al. The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function. Nucleic Acids Res. 2015;43(14):6934\u201344. https:\/\/doi.org\/10.1093\/nar\/gkv623.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"8979_CR28","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1074\/jbc.M114.624718","volume":"290","author":"IK Kim","year":"2015","unstructured":"Kim IK, Stegeman RA, Brosey CA, Ellenberger T. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly (ADP-ribose) polymerase 1 by poly (ADP-ribose) glycohydrolase. J Biol Chem. 2015;290(6):3775\u201383. https:\/\/doi.org\/10.1074\/jbc.M114.624718.","journal-title":"J Biol Chem"},{"issue":"14","key":"8979_CR29","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.molcel.2021.05.009","volume":"81","author":"AA Demin","year":"2021","unstructured":"Demin AA, Hirota K, Tsuda M, Adamowicz M, Hailstone R, Brazina J, et al. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Mol Cell. 2021;81(14):3018\u201330. https:\/\/doi.org\/10.1016\/j.molcel.2021.05.009.","journal-title":"Mol Cell"},{"issue":"17","key":"8979_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1101\/gad.1331805","volume":"19","author":"MY Kim","year":"2005","unstructured":"Kim MY, Zhang T, Kraus WL. Poly (ADP-ribosyl) ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 2005;19(17):1951\u201367. https:\/\/doi.org\/10.1101\/gad.1331805.","journal-title":"Genes Dev"},{"issue":"4","key":"8979_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/iub.432","volume":"63","author":"L Delavall\u00e9e","year":"2011","unstructured":"Delavall\u00e9e L, Cabon L, Gal\u00e1n-Malo P, Lorenzo HK, Susin SA. AIF-mediated caspase-independent necroptosis: a new chance for targeted therapeutics. IUBMB Life. 2011;63(4):221\u201332. https:\/\/doi.org\/10.1002\/iub.432.","journal-title":"IUBMB Life"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08979-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T15:04:08Z","timestamp":1637161448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08979-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8979"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08979-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1234"}}